No Blood Clot Risk From Covishield, Covaxin: Top Government Panel

Last week, leading EU countries said they would resume the use of AstraZeneca vaccine as the European medical regulator said the jab is "safe and effective".

A high-level government panel has concluded there is no increased risk of blood clotting so far linked to Covishield and Covaxin, the vaccines that India's drug regulator DCGI (Drugs Controller General of India) cleared earlier this year. The assurance comes after several European nations, a few days ago, temporarily paused the rollout of AstraZeneca vaccine over blood clot fears. #Unite2FightCorona#LargestVaccineDriveA record 32,53,095 COVID19 vaccinations in the last 24 hours. pic.twitter.com/W0z580GtTO Last week, leading EU countries said they would resume the use of vaccine as the European medical regulator said the jab is "safe and effective". Pune-based Serum Institute of India's Covishield has been developed in partnership with the Oxford University and British-Swedish pharmaceutical giant AstraZeneca. India began public rollout of coronavirus vaccines on March 1 for people above 60 years of age and those above 45 with serious illnesses.